TOP TEN perturbations for 38715_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38715_at
Selected probe(set): 214407_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38715_at (214407_x_at) across 6674 perturbations tested by GENEVESTIGATOR:

systemic onset JIA study 4 / juvenile enthesitis related arthritis study 2 (ERA)

Relative Expression (log2-ratio):6.748664
Number of Samples:3 / 3
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control juvenile enthesitis related arthritis study 2 (ERA)
Peripheral blood mononuclear cell (PBMC) samples from children with enthesitis related arthritis (ERA).

systemic onset JIA study 4 / oligoarticular JIA study 3

Relative Expression (log2-ratio):6.3771877
Number of Samples:3 / 12
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control oligoarticular JIA study 3
Peripheral blood mononuclear cell (PBMC) samples from children with persistent oligoarthritis (oligoarticular JIA).

systemic onset JIA study 5 / oligoarticular JIA study 2

Relative Expression (log2-ratio):6.3533163
Number of Samples:3 / 12
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control oligoarticular JIA study 2
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of persistent oligoarticular juvenile idiopathic arthritis (JIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 5 / normal PBMC sample

Relative Expression (log2-ratio):6.107894
Number of Samples:3 / 27
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

systemic onset JIA study 4 / normal PBMC sample

Relative Expression (log2-ratio):5.9820156
Number of Samples:3 / 27
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

systemic onset JIA study 5 / polyarticular JIA study 4 (RF negative)

Relative Expression (log2-ratio):5.9568367
Number of Samples:3 / 17
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control polyarticular JIA study 4 (RF negative)
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of polyarticular juvenile idiopathic arthritis, rheumatoid factor negative (polyJIA, RF neg.). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 4 / polyarticular JIA study 6

Relative Expression (log2-ratio):5.7088223
Number of Samples:3 / 14
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control polyarticular JIA study 6
Peripheral blood mononuclear cell (PBMC) samples from children with rheumatoid factor negative polyarthritis (RF- polyarthritis/RF- polyarticular JIA).

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-4.614958
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

systemic onset JIA study 3 / polyarticular JIA study 3 (RF positive)

Relative Expression (log2-ratio):4.0786858
Number of Samples:18 / 15
Experimental systemic onset JIA study 3
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA). All patients were free of disease modifying antirheumatic drugs.
Control polyarticular JIA study 3 (RF positive)
Peripheral blood mononuclear cell (PBMC) samples from children with rheumatoid factor negative (RFpos) polyarticular juvenile rheumatoid arthritis. All patients were free of disease modifying antirheumatic drugs.

sickle cell disease study 2 (Pax) / normal blood sample

Relative Expression (log2-ratio):4.0749187
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Pax)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion step.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit followed by an on-column DNase digestion step.